On the aetiology of Hodgkin lymphoma

Danish Medical Journal

Volumn 59, Issue 7, 2012, Pages

  Hjalgrim, Henrik ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASIA; BIOLOGICAL MODEL; CANCER EPIDEMIOLOGY; CANCER RISK; CONFOUNDING VARIABLE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EPSTEIN BARR VIRUS INFECTION; HODGKIN DISEASE; HUMAN; IMMUNOLOGY; INCIDENCE; MONONUCLEOSIS; RISK FACTOR; SINGAPORE; SOCIOECONOMICS; ETHNOLOGY; REVIEW; SCANDINAVIA; VIROLOGY;

ASIA; EPSTEIN-BARR VIRUS INFECTIONS; HODGKIN DISEASE; HUMANS; INCIDENCE; RISK FACTORS; SCANDINAVIA;

EID: 84873134688     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (198)

1. Hodgkin T. On some morbid appearances of the absorbent glands and spleen. Medical-Chirurgical Transactions 1832;17:68-114.
2. Kaplan H. Hodgkin's disease. Cambrigde, Massachussetts: Harvard University Press, 1972.
3. Wilks S. Cases of enlargement of the lymphatic glands and spleen (or, Hodgkin's Disease,) with remarks. Guy's Hospital Reports 1865;11:56-67.
4. Stein RS, Morgan DS. Hodgkin disease. In: Wintrobe's Clinical Hematology, Greer JP, Foester J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, eds., vol. II, 11th ed. Philadelphia: Lippincott Williams & Wilkins, 2004 2521-2554.
5. Armitage JO. Early-stage Hodgkin's lymphoma. New England Journal of Medicine 2010;363:653-662.
6. MacMahon B. Epidemiological evidence of the nature of Hodgkin's disease. Cancer 1957;10:1045-1054.
7. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Research 1966;26:1189-1200.
8. Newell GR. Etiology of multiple sclerosis and Hodgkin's disease. American Journal of Epidemiology 1970;91:119-122.
9. Correa P, O'Conor GT. Epidemiologic patterns of Hodgkin's disease. International Journal of Cancer 1971;8:192-201.
10. Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma, introduction. In: WHO classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al., eds. Lyon: International Agency for Research of Cancer, 2008 326-329.
11. Poppema S, Delsol G, Pileri SA, et al. Nodular lymphocyte predominant Hodgkin lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al., eds. Lyon: International Agency for Research of Cancer, 2008 323-325.
12. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. Journal of Experimental Medicine 1996;184:1495-1505.
13. Muschen M, Rajewsky K, Brauninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. Journal of Experimental Medicine 2000;191:387-394.
14. Stein H, Delsol G, Pileri S, et al. Classical Hodgkin lymphoma. In: World Health Organization classification of tumours, pathology and genetics. Tumours of haematopoietic and lymphoid tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Lyon: International Agency for Research of Cancer, 2001 244-253.
15. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of lymphomas: a work in progress. Annals of Oncology 1998;9 Suppl 5:S25-S30.
16. Harris NL. Hodgkin's disease: classification and differential diagnosis. Modern Pathology 1999;12:159-175.
17. Banks PM. Changes in diagnosis of non-Hodgkin's lymphomas over time. Cancer Research 1992;52S:5453s-5455s.
18. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695-708.
19. Harris NL. Hodgkin's lymphomas: classification, diagnosis, and grading. Seminars in Hematology 1999;36:220-232.
20. Flavell KJ, Biddulph JP. Epidemiogy of Epstein-Barr Virusassociated Hodgkin's Disease. Epstein-Barr Virus Report 2001;8:69-77.
21. Stein H, von Wasielewski R, Poppema S, MacLennan K, Guenova M. Nodular sclerosis classical Hodgkin lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al., eds. Lyon: International Agency for Research of Cancer, 2008 330-330.
22. Weiss LM, von Wasielewski R, Delsol G, Poppema S, Stein H. Mixed cellularity classical Hodgkin lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al., eds. Lyon: International Agency for Research of Cancer, 2008 331-331.
23. Anagnostopoulos I, Isaacson PG, Stein H. Lymphocyte-rich classical Hodgkin lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al., eds. Lyon: International Agency for Research of Cancer, 2008 332-333.
24. Benharroch D, Stein H, Peh SC. Lymphocyte-depleted classical Hodgkin lymphoma. In: WHO classification of tumours of haematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al., eds. Lyon: International Agency for Research of Cancer, 2008 334-334.
25. Franssila KO, Heiskala MK, Heiskala HJ. Epidemiology and histopathology of Hodgkin's disease in Finland. Cancer 1977;39:1280-1288.
26. Glaser SL, Swartz WG. Time trends in Hodgkin's disease incidence. The role of diagnostic accuracy. Cancer 1990;66:2196-2204.
27. Lauritzen AF, Specht LK, Nissen NI, Hou-Jensen K. Changes over the course of time in histological subclassification of Hodgkin's disease in Denmark. Danish Medical Bulletin 1991;38:84-87.
28. Dige U, Johansson H, Lenner P, Norberg B, Roos G. Hodgkin's disease in Northern Sweden, 1971-1981. i. a histopathological reevaluation of 223 cases. Acta Oncologica 1991;30:593-596.
29. Martinsson U, Glimelius B, Sundstrom C. Lymphoma incidence in a Swedish county during 1969-1987. Acta Oncologica 1992;31:275-282.
30. Georgii A, Fischer R, Hubner K, Schwarze EW, Bernhards J. Classification of Hodgkin's disease biopsies by a panel of four histopathologists. Report of 1,140 patients from the German National Trial. Leukemia and Lymphoma 1993;9:365-370.
31. Glaser SL, Dorfman RF, Clarke CA. Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: interobserver reliability and impact on incidence and survival rates. Cancer 2001;92:218-224.
32. Jarrett RF, Krajewski AS, Angus B, et al. The Scotland and Newcastle epidemiological study of Hodgkin's disease: impact of histopathological review and EBV status on incidence estimates. Journal of Clinical Pathology 2003;56:811-816.
33. Specht L, Hasenclever D. Prognostic Factors in Hodgkin Lymphoma. In: Hodgkin's Disease, Hoppe R, Mauch PM, Armitage JO, eds. Lippincott Williams & Wilkins, 2007 157-174.
34. Abramson JH. Childhood experience and Hodgkin's disease in adults. An interpretation of incidence data. Israel Journal of Medical Sciences 1974;10:1365-1370.
35. Gutensohn N, Cole P. Epidemiology of Hodgkin's disease in the young. International Journal of Cancer 1977;19:595-604.
36. Devore JW, Doan CA. Studies in Hodgkin's syndrome. XII. Hereditary and epidemiologic aspects. Annals of Internal Medicine 1957;47:300-316.
37. Razis DV, Diamond HD, Craver LF. Familial Hodgkin's disease: its significance and implications. Annals of Internal Medicine 1959;51:933-971.
38. Grufferman S, Cole P, Smith PG, Lukes RJ. Hodgkin's disease in siblings. New England Journal of Medicine 1977;296:248-250.
39. Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin's disease in identical twins suggesting genetic suscep tibility to the young-adult form of the disease. New England Journal of Medicine 1995;332:413-418.
40. Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 2004;100:1902-1908.
41. Newell GR, Cole SR, Miettinen OS, MacMahon B. Age differences in the histology of Hodgkin's disease. Journal of the National Cancer Institute 1970;45:311-317.
42. Henderson BE, Dworsky R, Pike MC, et al. Risk factors for nodular sclerosis and other types of Hodgkin's disease. Cancer Research 1979;39:4507-4511.
43. Glaser SL. Regional variation in Hodgkin's disease incidence by histologic subtype in the US. Cancer 1987;60:2841-2847.
44. Cozen W, Katz J, Mack TM. Risk patterns of Hodgkin's disease in Los Angeles vary by cell type. Cancer Epidemiology Biomarkers and Prevention 1992;1:261-268.
45. Macfarlane G, Evstifeeva T, Boyle P, Grufferman S. International patterns in the occurrence of Hodgkin's disease in children and young adult males. International Journal of Cancer 1995;61:165-169.
46. Cole P, MacMahon B, Aisenberg A. Mortality from Hodgkin's disease in the United States. Evidence for the multipleaetiology hypothesis. Lancet 1968;2:1371-1376.
47. MacMahon B, Cole P, Newell GR. Hodgkin's disease: one entity or two? Lancet 1971;1:240-241.
48. Jarrett RF, Gallagher A, Jones DB, et al. Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. Journal of Clinical Pathology 1991;44:844-848.
49. Armstrong AA, Alexander FE, Cartwright RA, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia 1998;12:1272-1276.
50. Weiss L, Strickler J, Warnke R, Purtilo D, Sklar J. Epstein-Barr viral DNA in tissues of Hodgkin's disease. American Journal of Pathology 1987;129:86-91.
51. Uccini S, Monardo F, Ruco LP, et al. High frequency of Epstein-Barr virus genome in HIV-positive patients with Hodgkin's disease. Lancet 1989;1:1458.
52. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989;74:810-816.
53. Boiocchi M, Carbone A, Re VD, Dolcetti R. Is the Epstein-Barr virus involved in Hodgkin's disease? Tumori 1989;75:345-350.
54. Herbst H, Tippelmann G, Anagnostopoulos I, et al. Immunoglobulin and T-cell receptor gene rearrangements in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma: dissociation between phenotype and genotype. Leukemia Research 1989;13:103-116.
55. Staal SP, Ambinder R, Beschorner WE, Hayward GS, Mann R. A survey of Epstein-Barr virus DNA in lymphoid tissue. Frequent detection in Hodgkin's disease. American Journal of Clinical Pathology 1989;91:1-5.
56. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. New England Journal of Medicine 1989;320:502-506.
57. Wu TC, Mann RB, Charache P, et al. Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. International Journal of Cancer 1990;46:801-804.
58. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease [see comments]. Lancet 1991;337:320-322.
59. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virusassociated Hodgkin's disease: epidemiologic characteristics in international data. International Journal of Cancer 1997;70:375-382.
60. Young GA. Lymphoma. In: World Cancer Report, Stewart BW, Kleihues P, eds. IARC Press, 2003 237-241.
61. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, vol VIII. Lyon: International Agency for Research of Cancer, 2002.
62. Engholm G, Ferlay J, Christensen N, et al. PC-NORDCAN: Cancer Incidence and Mortality in the Nordic Countries, Version 2.4., 2009.
63. Parkin DM, Whelan S, Ferlay J, Storm H. Cancer Incidence in Five Continents, Vol. I to VIII. IARC CancerBase No. 7, Lyon, 2005.
64. Dorken H. Uber die Altersverteilung der Lymphogranulomatose. Klinische Wochenschrift 1960;38:944-947.
65. Clemmesen J, Sorensen J. Malignant neoplasias of haematopoietic and connective tissues in various countries. Cancer incidence in Denmark 1943 to 1953 V. Danish Medical Bulletin 1958;5:73-123.
66. Clemmesen J. Statistical studies in the aetiology of malignant neoplasms, vol. I. Munksgaard, Kobenhavn, 1965.
67. Glaser SL, Hsu JL. Hodgkin's disease in Asians: incidence patterns and risk factors in population-based data. Leukemia Research 2002;26:261-269.
68. Hartge P, Devesa SS, Fraumeni Jr JF. Hodgkin's and non-Hodgkin's lymphomas. Cancer Surveys 1994;19/20:423-453.
69. Chen YT, Zheng TZ, Chou MC, Boyle P, Holford TR. The increase of Hodgkin's disease among young adults. Experience in Connecticut, 1935-1992. Cancer 1997;79:2209-2218.
70. Liu S, Semenciw R, Waters C, Wen SW, Mao Y. Time trends and sex patterns in Hodgkin's disease incidence in Canada, 1970-1995. Canadian Journal of Public Health 2000;91:188-192.
71. Clavel J, Steliarova-Foucher E, Berger C, Danon S, Valerianova Z. Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the Automated Cancer Information System project. European Journal of Cancer 2006;42:2037-2049.
72. Ariad S, Lipshitz I, Benharroch D, Gopas J, Barchana M. A sharp rise in the incidence of Hodgkin's lymphoma in young adults in Israel. Israel Medical Association Journal 2009;11:453-455.
73. Cartwright R, McNally R, Roman E, Simpson J, Thomas J. Incidence and time trends in Hodgkin's disease: from parts of the United Kingdom (1984-1993). Leukaemia and Lymphoma 1998;31:367-377.
74. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Research 1992;52S:5432s-5440s.
75. Sandin S, Hjalgrim H, Glimelius B, Rostgaard K, Pukkala E, Askling J. Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiology, Biomarkers and Prevention 2006;15:1295-1300.
76. Seow A, Koh W, Chia K, Shi L, Lee H, Shanmugaratnam K. Trends in Cancer Incidence in Singapore 1968-2002. 6. Singapore Cancer Registry, Singapore, 2004.
77. Hartge P, Devesa SS. Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Research 1992;52S:5566s-5569s.
78. Glaser SL. Recent incidence and secular trends in Hodgkin's disease and its histologic subtypes. Journal of Chronic Diseases 1986;39:789-798.
79. Clarke CA, Glaser SL, Keegan THM, Stroup A. Neighborhood socioeconomic status and Hodgkin's lymphoma incidence in California. Cancer Epidemiology Biomarkers Prevention 2005;14:1441-1447.
80. Gutensohn N, Li FP, Johnson RE, Cole P. Hodgkin's disease, tonsillectomy and family size. New England Journal of Medicine 1975;292:22-25.
81. Paffenbarger Jr RS, Wing AL, Hyde RT. Characteristics in youth indicative of adult-onset Hodgkin's disease. Journal of the National Cancer Institute 1977;58:1489-1491.
82. Gutensohn N, Cole P. Childhood Social Environment and Hodgkin's Disease. New England Journal of Medicine 1981;304:135-140.
83. Bernard SM, Cartwright RA, Darwin CM, et al. Hodgkin's disease: case control epidemiological study in Yorkshire. British Journal of Cancer 1987;55:85-90.
84. Bonelli L, Vitale V, Bistolfi F, Landucci M, Bruzzi P. Hodgkin's disease in adults: association with social factors and age at tonsillectomy. a case-control study. International Journal of Cancer 1990;45:423-427.
85. Westergaard T, Melbye M, Pedersen JB, Frisch M, Olsen JH, Andersen PK. Birth order, sibship size and risk of Hodgkin's disease in children and young adults: a population-based study of 31 million person-years. International Journal of Cancer 1997;72:977-981.
86. Abramson JH, Pridan H, Sacks MI, Avitzour M, Peritz E. A case-control study of Hodgkin's disease in Israel. Journal National Cancer Institute 1978;61:307-314.
87. Serraino D, Franceschi S, Talamini R, et al. Socio-economic indicators, infectious disease and Hodgkin's disease. International Journal of Cancer 1991;47:352-357.
88. Vineis P, Miligi L, Crosignani P, et al. Delayed infection, family size and malignant lymphomas. Journal of Epidemiology and Community Health 2000;54:907-911.
89. Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF. Social class and risk of Hodgkin's disease in young-adult women in 1988-94. International Journal of Cancer 2002;98:110-117.
90. Chang ET, Montgomery SM, Richiardi L, Ehlin A, Ekbom A, Lambe M. Number of siblings and risk of Hodgkin's lymphoma. Cancer Epidemiology Biomarkers and Prevention 2004;13:1236-1243.
91. Chang ET, Zheng T, Weir EG, et al. Childhood social environment and Hodgkin's lymphoma: new findings from a population-based case-control study. Cancer Epidemiology Biomarkers and Prevention 2004;13:1361-1370.
92. Morton LM, Cahill J, Hartge P. Reporting participation in epidemiologic studies: a survey of practice. American Journal of Epidemiology 2006;163:197-203.
93. Glaser SL, Clarke CA, Keegan TH, et al. Attenuation of social class and reproductive risk factor associations for Hodgkin lymphoma due to selection bias in controls. Cancer Causes Control 2004;15:731-739.
94. Lukes RJ, Tindle BH, Parker JW. Reed-Sternberg-like cells in infectious mononucleosis. Lancet 1969;2:1003-1004.
95. Evans AS. The spectrum of infections with Epstein-Barr virus: a hypothesis. Journal of Infectious Diseases 1971;124:330-337.
96. Niederman JC, Evans AS. Epstein-Barr virus. In: Viral infections of humans. Epidemiology and control, Evans AS, Kaslow RA, eds., 4th ed. New York: Plenum Medical Book Company, 1997 253-284.
97. IARC Monographs on the evaluation of carcinogenic risks to humans: Epstein-Barr virus and Kaposi's sarcoma herpesvirus/ herpesvirus 8. 70. Lyon: International Agency for Research of Cancer, 1997.
98. Evans AS. Infectious mononucleosis and related syndromes. American Journal of Medical Sciences 1978;276:325-339.
99. Hurt C, Tammaro D. Diagnostic evaluation of mononucleosis-like illnesses. American Journal of Medicine 2007;120:911. e1-911. e8.
100. Thomsen S. Studier over Mononucleosis Infectiosa paa Basis af 549 Tilfalde (In Danish). Ph.D. thesis, University of Copenhagen, 1942.
101. Nye FJ. Social class and infectious mononucleosis. Journal of Hygiene (London) 1973;71:145-149.
102. Rosdahl N, Olesen Larsen S, Thamdrup AB. Infectious mononucleosis in Denmark-epidemiological observations based on positive Paul-Bunnell reactions from 1940 to 1969. Scandinavian Journal of Infectious Diseases 1973;5:163-170.
103. Connelly RR, Christine BW. A cohort study of cancer following infectious mononucleosis. Cancer Research 1974;34:1172-1178.
104. Evans AS, Comstock GW. Presence of elevated antibody titres to Epstein-Barr virus before Hodgkin's disease. Lancet 1981;i:1183-1186.
105. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. New England Journal of Medicine 1989;320:689-695.
106. Lehtinen T, Lumio J, Dillner J, et al. Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies-a prospective study. Cancer Causes Control 1993;4:187-193.
107. Kuppers R. The biology of Hodgkin's lymphoma. Nature Reviews Cancer 2009;9:15-27.
108. Grasser FA, Murray PG, Kremmer E, et al. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease. Blood 1994;84:3792-3798.
109. Miller RW, Beebe GW. Infectious mononucleosis and the empirical risk of cancer. Journal of the National Cancer Institute 1973;50:315-321.
110. Rosdahl N, Olesen Larsen S, Clemmesen J. Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience. BMJ 1974;2:253-256.
111. Carter CD, Brown Jr TM, Herbert JT, Heath Jr CW. Cancer incidence following infectious mononucleosis. American Journal of Epidemiology 1977;105:30-36.
112. Munoz N, Davidson RJ, Witthoff B, Ericsson JE, de The G. Infectious mononucleosis and Hodgkin's disease. International Journal of Cancer 1978;22:10-13.
113. Kvale G, Hojby EA, Pedersen E. Hodgkin's disease in patients with previous infectious mononucleosis. International Journal of Cancer 1979;23:593-597.
114. Lumio J, Karjalainen S. Patients treated in hospital for infectious mononucleosis and risk of cancer. Scandinavian Journal of Infectious Diseases 1993;25:283-288.
115. Goldacre MJ, Wotton CJ, Yeates DG. Associations between infectious mononucleosis and cancer: record-linkage studies. Epidemiology and Infection 2009;137:672-80.
116. Newell GR, Rawlings W, Kinnear BK, et al. Case-control study of Hodgkin's disease. i. results of the interview questionnaire. Journal National Cancer Institute 1973;51:1437-1441.
117. Gutensohn N. Social class and age at diagnosis of Hodgkin's disease: new epidemiological evidence for the "twodisease hypothesis". Cancer Treatment Reports 1982;66:689-695.
118. Levine R, Zhu K, Gu Y, et al. Self-reported infectious mononucleosis and 6 cancers: a population-based, case-control study. Scandinavian Journal of Infectious Diseases 1998;30:211-214.
119. Tavani A, Vecchia CL, Franceschi S, Serraino D, Carbone A. Medical history and risk of Hodgkin's and non-Hodgkin's lymphomas. European Journal of Cancer Prevention 2000;9:59-64.
120. Alexander FE, Jarrett RF, Lawrence D, et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. British Journal of Cancer 2000;82:1117-1121.
121. Vineis P, Crosignani P, Sacerdote C, et al. Haematopoietic cancer and medical history: a multicentre case control study. Journal of Epidemiology and Community Health 2000;54:431-436.
122. Alexander FE, Lawrence DJ, Freeland J, et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV+ve HD in young adults. International Journal of Cancer 2003;107:298-302.
123. Monnereau A, Orsi L, Troussard X, et al. History of infections and vaccinations and risk of lymphoid neoplasms: does influenza immunization reduce the risk? Leukemia 2007;21:2075-2079.
124. Newton R, Crouch S, Ansell P, et al. Hodgkin's lymphoma and infection: findings from a UK case-control study. British Journal of Cancer 2007;97:1310-1314.
125. Becker N, Fortuny J, Alvaro T, et al. Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH). Journal of Cancer Research and Clinical Oncology 2009;135:1099-1107.
126. Karunanayake CP, Singh GV, Spinelli JJ, et al. Occupational exposures and Hodgkin lymphoma: Canadian case-control study. Journal of Occupational and Environmental Medicine 2009;51:1447-1454.
127. Mueller N. Epstein-Barr virus and Hodgkin's disease: an epidemiological paradox. Epstein-Barr Virus Report 1997;4:1-2.
128. Delecluse HJ, Marafioti T, Hummel M, Dallenbach F, Anagnostopoulos I, Stein H. Disappearance of the Epstein-Barr virus in a relapse of Hodgkin's disease. Journal of Pathology 1997;182:475-479.
129. Ambinder RF. Gammaherpesviruses and "Hit-and-Run" oncogenesis. Americal Journal of Pathology 2000;156:1-3.
130. Hjalgrim H, Friborg J, Melbye M. The epidemiology of EBV and its association with malignant disease. In: Human Herpesviruses-Biology, Therapy, and Immunoprophylaxis, Arvin A, Campadelli-Fiume G, Mocarski E, et al., eds. Cambridge: Cambridge University Press, 2007 929-959.
131. Smedby KE, Hjalgrim H, Chang ET, et al. Childhood social environment and risk of non-Hodgkin lymphoma in adults. Cancer Research 2007;67:11074-11082.
132. Cartwright RA, McKinney PA, O'Brien C, et al. Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire. Leukemia Research 1988;12:81-88.
133. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control 2004;15:419-428.
134. Holly EA, Bracci PM. Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco. American Journal of Epidemiology 2003;158:316-327.
135. Bernstein L, Ross RK. Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County. Cancer Research 1992;52S:5510s-5515s.
136. Glaser SL, Keegan TH, Clarke CA, et al. Exposure to childhood infections and risk of Epstein-Barr virus-defined Hodgkin's lymphoma in women. International Journal of Cancer 2005;115:599-605.
137. Sleckman BG, Mauch PM, Ambinder RF, et al. Epstein-Barr virus in Hodgkin's disease: correlation of risk factors and disease characteristics with molecular evidence of viral infection. Cancer Epidemiology, Biomarkers and Prevention 1998;7:1117-1121.
138. Chang ET, Zheng T, Lennette ET, et al. Heterogeneity of risk factors and antibody profiles in Epstein-Barr virus genomepositive and-negative Hodgkin lymphoma. Journal of Infectious Diseases 2004;189:2271-2281.
139. Vestlev PM, Pallesen G, Sandvej K, Hamilton-Dutoit SJ, Bendtzen SM. Prognosis of Hodgkin's disease is not influenced by Epstein-Barr virus latent membrane protein. International Journal of Cancer 1992;50:670-671.
140. Enblad G, Sandvej K, Sundstrom C, Pallesen G, Glimelius B. Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. Acta Oncologica 1999;38:425-429.
141. Evans AS, Niederman JC, Cenabre LC, West B, Richards VA. A prospective evaluation of heterophile and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: specificity and sensitivity of the tests and persistence of antibody. Journal of Infectious Diseases 1975;132:546-554.
142. Bruu AL, Hjetland R, Holter E et al. Evaluation of 12 commercial tests for detection of Epstein-Barr virus-specific and heterophile antibodies. Clinical and Diagnostic Laboratory Immunology 2000;7:451-456.
143. Goldman R, Fishkin BG, Peterson ET. The value of the heterophile antibody reaction in the lymphomatous diseases. Journal of Laboratory and Clinical Medicine 1950;35:681-687.
144. Davidsohn I, Lee CL. The laboratory in the diagnosis of infectious mononucleosis, with additional notes on epidemiology, etiology and pathogenesis. Medical Clinics of North America 1962;46:225-244.
145. Wolf P, Dorfman R, McClenahan J, Collins F. Falsepositive infectious mononucleosis spot test in lymphoma. Cancer 1970;25:626-628.
146. Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 2005;106:2444-2451.
147. Diepstra A, van Imhoff GW, Schaapveld M, et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients. Journal of Clinical Oncology 2009;27:3815-3821.
148. Grulich AE, Vajdic CM, Falster MO, et al. Birth order and risk of non-Hodgkin lymphoma-true association or bias? American Journal of Epidemiology 2010;172:621-630.
149. Birch-Johansen F, Hvilsom G, Kjaer T, Storm H. Social inequality and incidence of and survival from malignant melanoma in a population-based study in Denmark, 1994-2003. European Journal of Cancer 2008;44:2043-2049.
150. Dalton SO, Steding-Jessen M, Engholm G, Schuz J, Olsen JH. Social inequality and incidence of and survival from lung cancer in a population-based study in Denmark, 1994-2003. European Journal of Cancer 2008;44:1989-1995.
151. Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO. Reliability of self-reported family history of cancer in a large case-control study of lymphoma. Journal of the National Cancer Institute 2006;98:61-68.
152. Levine PH, Pallesen G, Ebbesen P, Harris N, Evans AS, Mueller N. Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin's disease. International Journal of Cancer 1994;59:48-50.
153. Enblad G, Sandvej K, Lennette E, et al. Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. International Journal of Cancer 1997;72:394-397.
154. Gallagher A, Perry J, Freeland J, et al. Hodgkin lymphoma and Epstein-Barr virus (EBV): no evidence to support hit-and run mechanism in cases classified as non-EBV-associated. International Journal of Cancer 2003;104:624-630.
155. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annual Review of Microbiology 2000;54:19-48.
156. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annual Review of Immunology 2007;25:587-617.
157. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with hiv/aids compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007;370:59-67.
158. Audouin J, Diebold J, Pallesen G. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients. Journal of Pathology 1992;167:381-384.
159. Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood 1993;82:619-624.
160. Herndier BG, Sanchez HC, Chang KL, Chen YY, Weiss LM. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of HIV-associated Hodgkin's disease. American Journal of Pathology 1993;142:1073-1079.
161. Garnier JL, Lebranchu Y, Dantal J, et al. Hodgkin's disease after transplantation. Transplantation 1996;61:71-76.
162. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. Journal of Clinical Oncology 1999;17:3122-3127.
163. Khan G, Lake A, Shield L, et al. Phenotype and frequency of Epstein-Barr virus-infected cells in pretreatment blood samples from patients with Hodgkin lymphoma. British Journal of Haematology 2005;129:511-519.
164. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. International Journal of Cancer 1999;84:442-448.
165. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet 2005;365:2216-2224.
166. Niens M, van den Berg A, Diepstra A, et al. The human leukocyte antigen class I region is associated with EBV-positive Hodgkin's lymphoma: HLA-A and HLA complex group 9 are putative candidate genes. Cancer Epidemiology, Biomarkers and Prevention 2006;15:2280-2284.
167. Niens M, Jarrett RF, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 2007;110:3310-3315.
168. Ryder LP, Svejgaard A, Dausset J. Genetics of HLA disease association. Annual Review of Genetics 1981;15:169-187.
169. Hors J, Dausset J. HLA and susceptibility to Hodgkin's disease. Immunological Reviews 1983;70:167-192.
170. McAulay KA, Higgins CD, Macsween KF, et al. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. Journal of Clinical Investigation 2007;117:3042-3048.
171. Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and-negative Hodgkin's disease. Blood 1996;87:3844-3851.
172. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 1998;92:2477-2483.
173. Diepstra A, Poppema S, Boot M, et al. HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens 2008;71:219-226.
174. Chapman AL, Rickinson AB, Thomas WA, Jarrett RF, Crocker J, Lee SP. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy. Cancer Research 2001;61:6219-6226.
175. Straathof KC, Leen AM, Buza EL, et al. Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma. Journal of Immunology 2005;175:4137-4147.
176. Brennan RM, Burrows SR. A mechanism for the HLAA* 01-associated risk for EBV+ Hodgkin lymphoma and infectious mononucleosis. Blood 2008;112:2589-2590.
177. Tan LC, Gudgeon N, Annels NE, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. Journal of Immunology 1999;162:1827-1835.
178. Bell MJ, Brennan R, Miles JJ, Moss DJ, Burrows JM, Burrows SR. Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response. Journal of Infectious Diseases 2008;197:1594-1597.
179. Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood 2008;111:1420-1427.
180. Begg CB, Zhang ZF. Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiology Biomarkers and Prevention 1994;3:173-175.
181. Levin L, Lennette E, Ambinder R, Chang E, Rubertone M, Mueller N. Prediagnosis Epstein-Barr virus serologic patterns in EBV-positive and EBV-negative Hodgkin's lymphoma. In: 10th International EBV Conference, Cairns. 2002 144.
182. Delsol G, Brousset P, Chittal S, Rigal-Huguet F. Correlation of the expression of Epstein-Barr virus latent membrane protein and in situ hybridization with biotinylated bamhi-w probes in Hodgkin's disease. American Journal of Pathology 1992;140:247-253.
183. Yang J, Lin L, Levin L, et al. Cell-free EBV is detected in patients with EBV(+) Hodgkin's lymphoma (HL) years in advance of diagnosis. In: 10th International EBV Conference, Cairns. 2002 57.
184. Chang ET, Zheng T, Weir EG, et al. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. Journal of the National Cancer Institute 2004;96:305-315.
185. Gandhi MK, Tellam JT, Khanna R. Epstein-Barr virusassociated Hodgkin's lymphoma. British Journal of Haematology 2004;125:267-281.
186. Enciso-Mora V, Broderick P, Ma Y, et al. A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). Nature Genetics 2010;42:1126-1130.
187. Jarrett RF, MacKenzie J. Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease. Seminars in Hematology 1999;36:260-269.
188. Jarrett RF. Viruses and Hodgkin's lymphoma. Annals of Oncology 2002;13 Suppl 1:23-29.
189. Jarrett RF. Viruses and lymphoma/leukaemia. Journal of Pathology 2006;208:176-186.
190. Cozen W, Hamilton AS, Zhao P, et al. A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma. Blood 2009;114:4014-4020.
191. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. New England Journal of Medicine 2010;362:875-885.
192. Flavell KJ, Billingham LJ, Biddulph JP, et al. The effect of Epstein-Barr virus status on outcome in age-and sex-defined subgroups of patients with advanced Hodgkin's disease. Annals of Oncology 2003;14:282-290.
193. Engel M, Essop MF, Close P, Hartley P, Pallesen G, Sinclair-Smith C. Improved prognosis of Epstein-Barr virus associated childhood Hodgkin's lymphoma: study of 47 South African cases. Journal of Clinical Pathology 2000;53:182-186.
194. Glavina-Durdov M, Jakic-Razumovic J, Capkun V, Murray P. Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease. British Journal of Cancer 2001;84:1227-1234.
195. Kwon JM, Park YH, Kang JH, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Annals of Hematology 2006;85:463-468.
196. Clarke CA, Glaser SL, Dorfman RF, et al. Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women. Cancer 2001;91:1579-1587.
197. Stark GL, Wood KM, Jack F, et al. Hodgkin's disease in the elderly: a population-based study. British Journal of Haematology 2002;119:432-440.
198. Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. Journal of Clinical Oncology 2005;23:7604-7613.